0001104659-23-079123.txt : 20230707 0001104659-23-079123.hdr.sgml : 20230707 20230707161119 ACCESSION NUMBER: 0001104659-23-079123 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20230707 DATE AS OF CHANGE: 20230707 EFFECTIVENESS DATE: 20230707 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NeuBase Therapeutics, Inc. CENTRAL INDEX KEY: 0001173281 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 465622433 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-486254 FILM NUMBER: 231076908 BUSINESS ADDRESS: STREET 1: 350 TECHNOLOGY DRIVE CITY: PITTSBURGH STATE: PA ZIP: 15219 BUSINESS PHONE: 412-763-3350 MAIL ADDRESS: STREET 1: 350 TECHNOLOGY DRIVE CITY: PITTSBURGH STATE: PA ZIP: 15219 FORMER COMPANY: FORMER CONFORMED NAME: Ohr Pharmaceutical Inc DATE OF NAME CHANGE: 20090819 FORMER COMPANY: FORMER CONFORMED NAME: BBM HOLDINGS, INC. DATE OF NAME CHANGE: 20070402 FORMER COMPANY: FORMER CONFORMED NAME: PRIME RESOURCE INC DATE OF NAME CHANGE: 20020513 D 1 primary_doc.xml X0708 D LIVE 0001173281 NeuBase Therapeutics, Inc. 350 TECHNOLOGY DRIVE PITTSBURGH PA PENNSYLVANIA 15219 412-763-3350 DELAWARE Ohr Pharmaceutical, Inc. Ohr Pharmaceutical Inc BBM HOLDINGS, INC. PRIME RESOURCE INC Corporation true Dietrich Stephan 350 Technology Drive Pittsburgh PA PENNSYLVANIA 15219 Executive Officer Director Todd Branning 350 Technology Drive Pittsburgh PA PENNSYLVANIA 15219 Executive Officer Dov Goldstein 350 Technology Drive Pittsburgh PA PENNSYLVANIA 15219 Director Eric Richman 350 Technology Drive Pittsburgh PA PENNSYLVANIA 15219 Director Franklyn Prendergast 350 Technology Drive Pittsburgh PA PENNSYLVANIA 15219 Director Gerald McDougall 350 Technology Drive Pittsburgh PA PENNSYLVANIA 15219 Director Biotechnology No Revenues 06b false 2023-06-28 false true true true false 0 H.C. Wainwright & Co., LLC 375 None None 430 PARK AVENUE 3RD FLOOR NEW YORK NY NEW YORK 10022 NY NEW YORK false 5000002 5000002 0 The total offering amount herein reflects aggregate purchase price received by the Company in connection with the sale by the Company of the securities to the investor in a concurrent registered direct offering and the aforementioned private placements. false 1 482389 0 The placement agent received $482,389.00 and warrants to purchase up to 136,187 shares of common stock exercisable at $3.2125 per share. Upon exercise of certain warrants, the Company will pay the placement agent an additional cash fee and warrants. 0 false NeuBase Therapeutics, Inc. /s/ Todd Branning Todd Branning Chief Financial Officer 2023-07-07